COVID19- Infection with SARS-CoV-2 Virus
Conditions
Keywords
Central precocious puberty, COVID-19 pandemic, GnRH analogs, pediatric endocrinology, lifestyle changes
Brief summary
Objective: This study investigates the clinical and demographic characteristics of girls diagnosed with central precocious puberty (CPP) in the pre-pandemic and pandemic periods to assess potential changes during the COVID-19 pandemic.
Detailed description
Methods: A retrospective cohort study was conducted on patients admitted to the Pediatric Endocrinology Departments of two centers in Turkey. Girls treated with GnRH analogs between March 2018 and 2022 were categorized into two groups: the pre-pandemic group (2018-2020) and the pandemic group (2020-2022). Clinical, anthropometric, and hormonal data were analyzed. Patients with organic lesions, genetic conditions, or medications affecting puberty were excluded.
Interventions
None listed
Sponsors
Umraniye Education and Research Hospital
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
(Who Can Participate?) Girls: Tanner stage ≥2 before age 8 peak LH \> on gnrh analog test, basal Lh \>0,3 Patients with organic lesions (e.g., hypothalamo-pituitary tumors), congenital malformations, oncological diseases, neurosurgical or genetic disorders, or medications affecting puberty were excluded from the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Age at Pubertal Onset | 4 years | Mean Age at Pubertal Onset Description: The mean age at pubertal onset will be compared between pre-pandemic and post-pandemic periods in both girls and boys. Time Frame: At baseline. Method of Measurement: Tanner staging, LH/FSH levels, and bone age assessment. |
Countries
Turkey (Türkiye)
Outcome results
None listed